share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4:持股变动声明-高管 Kulkarni Samarth

美股SEC公告 ·  01/18 00:00

Moomoo AI 已提取核心信息

CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics首席执行官萨玛斯·库尔卡尼于2024年1月16日完成了一项股票交易,涉及出售2万股普通股。这些股票以每股62.5029美元的价格出售,总交易价值为1,250,058美元。在此次出售之前,库尔卡尼行使了期权,以每股19.12美元的价格收购了相同数量的股票。交易完成后,库尔卡尼在该公司的直接持股量为187,377股股票。此外,库尔卡尼通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权。
CRISPR Therapeutics首席执行官萨玛斯·库尔卡尼于2024年1月16日完成了一项股票交易,涉及出售2万股普通股。这些股票以每股62.5029美元的价格出售,总交易价值为1,250,058美元。在此次出售之前,库尔卡尼行使了期权,以每股19.12美元的价格收购了相同数量的股票。交易完成后,库尔卡尼在该公司的直接持股量为187,377股股票。此外,库尔卡尼通过库尔卡尼2023年GRAT拥有20万股股票的间接实益所有权。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息